Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 trial to demonstrate intra-bladder route of administration (PK data) in cUTI patients with resistant E. Coli infections in the bladder

Trial Profile

A phase 1 trial to demonstrate intra-bladder route of administration (PK data) in cUTI patients with resistant E. Coli infections in the bladder

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 21 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PP 1493 (Primary) ; PP 1815 (Primary)
  • Indications Escherichia coli infections; Urinary tract infections
  • Focus Pharmacokinetics
  • Sponsors PHAXIAM Therapeutics
  • Most Recent Events

    • 15 May 2024 According to a PHAXIAM media release, company has received the validation from the ANSM (French Regulatory agency) to initiate this sponsored clinical trial in France, subject to available financing.
    • 29 Sep 2023 New trial record
    • 21 Sep 2023 According to a PHAXIAM media release, CTA submission in France planned before end of year 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top